Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024
Read More: Johnson & Johnson
UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
Read More: UroGen Pharma
EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy
Read More: EyePoint Pharmaceuticals
Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy
Read More: Edgewise Therapeutics
VYNE Therapeutics Reports the US FDA’s Acceptance of IND for VYN202 to Treat Autoimmune Diseases
Read More: VYNE Therapeutics
Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD
Read More: Modalis Therapeutics
Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss
Read More: Regeneron
Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease
Read More: Acumen Pharmaceuticals
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
Read More: Innovent Biologics
Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
Read More: Merck
Fusion Pharmaceuticals Doses First Patient with FPI-2265 in P-II Study for Metastatic Castration-Resistant Prostate Cancer
Read More: Fusion Pharmaceuticals
IRLAB Therapeutics Gains the Swedish Medical Products Agency’s Approval to Initiate P-I Trial of IRL757 for Apathy
Read More: IRLAB Therapeutics
BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma
Read More: BMS
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)
Read More: Innovent
Biotheryx Receives the US FDA’s IND Approval of BTX-9341 for Treating Breast Cancer
Read More: Biotheryx
BioVersys Extends its Strategic Collaboration with GSK and Series C Round by CHF 12.3M
Read More: BioVersys
IRLAB and McQuade Center for Strategic Research and Development (MSRD) Collaborate to Develop IRL757 for Apathy
Read More: IRLAB & McQuade Center
ARTBIO Partners with Nucleus RadioPharma to Manufacture Pb-212 Radiolabeled Therapeutic Products
Read More: ARTBIO & Nucleus RadioPharma
Flagship Pioneering and Metaphore Biotechnologies Partner with Novo Nordisk to Develop Therapies for Obesity
Read More: Flagship Pioneering, Metaphore Biotechnologies & Novo Nordisk
US Medical Innovations Reports the US FDA’s Clearance of Canady Helios Cold Plasma Ablation System for Soft Tissue Ablation
Read More: US Medical Innovations
Catalent’s Acquisition by Novo Holdings Put on Hold for 30 Days for Antitrust Review
Read More: Catalent & Novo
Arbor Biotechnologies to Acquire Serendipity Biosciences
Read More: Arbor Biotechnologies & Serendipity Biosciences
epiq Animal Health and KeraVet Bio Collaborate to Market KeraVet Gel for Wound Healing in Animals
Read More: epiq Animal Health & KeraVet Bio
Mozart Therapeutics Highlights Pre-clinical Data of KIR x ICOS CD8 Treg Modulator at Immunology 2024
Read More: Mozart Therapeutics
Seragon Biosciences Concludes SRN-901’s Pre-Clinical Study to Evaluate its Effect on Aging
Read More: Seragon Biosciences
The US FDA Grants Clearance to Indica Labs’ HALO AP Dx Digital Pathology Platform
Read More: Indica Labs
Related Post:- PharmaShots Weekly Snapshots (April 29 – May 03, 2024)